伐地那非病人勃起功能障碍（ED）

阴茎勃起失常（ED）症状更倾向用于Vardenafil（魏地那非）进行时疗法对ED药品Sildenafil（西地那非）和Vardenafil（魏地那非）进行时倾向相比较实验，愿意能够得到无病态取向的结果。波士顿-2006年9月20日，比对结果发表在《病态专文》上，同时在开罗开罗出席有可能会议的病态医学国际协有可能会第十二届筹备有可能会议上发布。这项比对极其独特，因为其数据来自一项关于PDE5（腺苷二脂酶5）可抑制药品的反之亦然对比诊疗试验，该试验用于PDE5可抑制药品来疗法ED症状。整个比对经过精心制作使得针对每种药品的病态取向约翻倍最小化。这是一项随机、双盲、交叉和反之亦然对比的诊疗试验，用于西地那非和魏地那非疗法患有ED、糖尿病、心肌梗死和/或高血脂的年长症状，相比较了二者的治果。得出在数个常用的必要病态常加权上魏地那非拿到了流行病学意涵上的竞争者，在医护人员评比和倾向病态的多个评估测试当中，魏地那非的平庸并不比西地那非差。计有1，057名年长参加了这项比对，他们首先倒数四个月份服用一种药品，然后是一个月份等待时间的缓冲期，接着再次倒数四个月份服用另一种药品。医护人员有可能会被问道这样的缺陷：“总的来说，你比如说用于那种药品？”此外还有其他11个有关ED疗法的缺陷。透过原本标准进行时附带必要病态评估在比对当中也被用于。数据结果显示38.9%的医护人员倾向用于魏地那非，而34.5%的医护人员愿意用于西地那非（26.6%的医护人员无倾向病态）。在阴茎勃起特病态，评比和大体上评比方面，魏地那非显著优于西地那非。在阴茎勃起时抽出硬度，阴茎勃起保持等待时间，全程保持和阴茎勃起信心方面，魏地那非也有更高%-的施打。这项比对的共同编者，病态专文的主编Irwin Goldstein 暗示说：“该比对断定我们对PDE5可抑制药品诊疗区隔的了解又前进了极为正要一步，肯定了魏地那非疗法ED的。”现在有三种PDE5可抑制药品可用于疗法ED，它们分别是西地那非，他约达那非和魏地那非。根据比对者的其实，所有这三种药品对一定范围内的老年人都平庸出必要病态和选择病态。来自反之亦然对比的诊疗实验数据（如本项比对）极其稀少，然而这样的比对结果有可能会帮助诊疗内科医生对西地那非、魏地那非和他约达那非加以区隔以选择最适当的药品供个体病症状用于。背景知识：ED：阴茎勃起失常 Erectile dysfunction, ED是常指持续不能约翻倍或者保持阴茎勃起以做到。ED比过去用的"阳萎"（Impotence）一词更确切，因为阳痿一词隐含一定歧病态的词。ED可按其程度包含轻、当中、正三度，阳痿属于正度的ED。70年代后由于阴茎勃起生理和组织学比对的进展，人们注意到固然无意识因素无论如何可以导致ED，但对大多数年长来说，ED与许多传染病（心肌梗死，糖尿病，心血管传染病）、药品、外伤及开刀等有关，因为阴茎勃起必要是颊膜上皮细胞松弛，血管壁扩展张，腹水降低和微血管回流受阻等完整血液物理操作过程，在这一操作过程当中，任何失常的病变可以包含： 器质病态ED 血管病态原因：包括任何有可能引发颊膜血管壁腹水减少的传染病，如：血管壁粥样硬化，血管壁损伤，血管壁狭窄，血管壁疏解及心特病态异常等，或有碍微血管回流闭合必要的白膜、很薄窦内上皮细胞减少致使的微血管漏。 骨骼肌病态原因：当实质上、向外骨骼肌传染病或损伤均可以引发阴茎勃起失常。 开刀与外伤：大血管开刀、腺癌根治术、颊阴茎膀胱腺癌根治术等开刀及骨盆骨折、腰椎压缩病态骨折或骑跨伤，可以导致起有关的血管和骨骼肌损伤，引发阴茎勃起失常。 内分泌精神障碍、慢病态病和长期服用某些药品也可以导致阴茎勃起失常。 本身传染病：如硬结症（Peyronie's disease）、弯曲畸形、严正背痛和龟头饲养炎。 无意识病态ED 常指紧张、负荷、抑郁、忧郁和夫妻感情不和等精神上无意识因素所致使的阴茎勃起失常。 混合病态ED 常指精神上无意识因素和器质病态病变共同引发的阴茎勃起失常。此外，由于器质病态ED仍未得到及时的疗法症状无意识负荷加正，害怕失败，使ED疗法更加趋向复杂。国内一组628例ED症状病变分类的比对断定：无意识病态占有39%。器质病态为15.8%，混合病态占有45.2%。PDE5可抑制PDE5是颊膜当中上皮细胞蛋白质第二信使NO-cGMP的分解酶。PDE5可抑制能够降低cGMP的溶解度，弱化颊膜上皮细胞的舒张作用，并促进病态刺激诱发的阴茎勃起化学反应。PDE5可抑制类药品对ED疗法具有最广泛应用的必要病态和选择病态。因此，该类药品被当作口服疗法药品的概要标准。现在，该类药品包括三种：西地那非、魏地那非和他约吉伦特非。西地那非在1998年，魏地那非和他莫那非则是在2003年得到当今世界认证。在诊疗用于以及诊疗对照比对当中发现，PDE5可抑制具有良好的选择病态和必要病态。在都可ED症状当中，诊疗比对充分证实上述三种药品的必要病态。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON 便是 September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.编辑：bluelove

编辑： Zhu